0000000000262854

AUTHOR

R. Luzzati

showing 2 related works from this author

Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry

2020

AbstractBackgroundCurrently, no data are available on the burden of morbidity and mortality in people with HIV-1 (PWH) harboring a 4-class drug-resistant (4DR) virus (nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors). The study aimed to assess the incidence of clinical events and death in this population.MethodsThis was a cohort study on PWH from the PRESTIGIO Registry with a documented 4DR virus. Burden of disease was defined as the occurrence of any new event including an AIDS-defining event (ADE) or non-AIDS-defining event (NADE) or death from any cause after 4DR evidence (baseline). Co…

0301 basic medicinemedicine.medical_specialty4-class drug resistance; AIDS-defining event; cancer; death; non-AIDS-defining event4-class drug resistancenon-AIDS-defining event.PopulationMajor ArticlesSettore MED/0703 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinedeathmedicinecancerCumulative incidenceAIDS-defining event030212 general & internal medicineeducationnon-AIDS-defining eventDisease burdeneducation.field_of_studyProportional hazards modelbusiness.industryIncidence (epidemiology)Hazard ratio030112 virologyAcademicSubjects/MED00290Infectious DiseasesOncologybusinessCohort study
researchProduct

Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing

2020

Abstract Background Few data are reported in the literature about the outcome of patients with severe extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) infections treated with ceftolozane/tazobactam (C/T), in empiric or definitive therapy. Methods A multicenter retrospective study was performed in Italy (June 2016–June 2019). Successful clinical outcome was defined as complete resolution of clinical signs/symptoms related to ESBL-E infection and lack of microbiological evidence of infection. The primary end point was to identify predictors of clinical failure of C/T therapy. Results C/T treatment was documented in 153 patients: pneumonia was the most common diagnosis (n = 46…

medicine.medical_specialtyceftolozane/tazobactammedicine.medical_treatmentCRRTTazobactamEnterobacteralesEnterobacteraleInternal medicineCRRT; ESBL; Enterobacterales; ceftolozane/tazobactam; septic shockMajor ArticlemedicineClinical endpointRenal replacement therapybusiness.industrySeptic shockRetrospective cohort studyOdds ratiomedicine.diseaseCeftolozane/tazobactam; CRRT; Enterobacterales; ESBL; Septic shockAcademicSubjects/MED00290Infectious DiseasesOncologyESBLseptic shockCeftolozanebusinessEmpiric therapymedicine.drugOpen forum infectious diseases
researchProduct